Skip to main content
SpringerLink
Log in

Drug Therapy for Adults with Attention-Deficit Hyperactivity Disorder

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Practitioners are increasingly called upon to diagnose and treat attention deficit hyperactivity disorder (ADHD) in adults. Although the use of pharmacotherapy in children with ADHD is well studied, the use of drugs for the treatment of adults with ADHD remains less well established.

A systematic review of the literature identified 15 studies (n = 482 patients) of stimulants, and 27 studies of nonstimulant medications (n = 1179 subjects) including antidepressants, norepinephrine reuptake inhibitors, antihypertensive agents, amino acids and wake-promoting agents for the treatment of ADHD in adults.

Controlled clinical trials in adults showed that stimulants, antidepressants and norepinephrine reuptake inhibitors demonstrated significant short-term improvements in ADHD symptoms compared with placebo. The two longer term trials with methylphenidate in adults confirmed the ongoing effectiveness and tolerability of stimulants. The response to amphetamine and methylphenidate appears to be dose-dependent. Methylphenidate and amphetamine had an immediate onset of action, whereas responses to pemoline, antidepressants and norepinephrine reuptake inhibitors appeared delayed. Controlled data on nicotinic/cholinergic compounds appear promising. Considerable variability was found in the diagnostic criteria for ADHD in adults, drug dosages and response rates between the various studies.

Under controlled conditions, the aggregate literature comprised mainly of short-term studies, shows that stimulants, norepinephrine reuptake inhibitors and specific antidepressants had clinically and statistically significant beneficial effects in the treatment of ADHD in adults. Cholinergic agents appear promising. Further studies are necessary to evaluate the long-term effectiveness and tolerability of various agents, functional and neuropsychological outcomes, and the use of various agents in specific subgroups of adults with ADHD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

Notes

  1. Use of tradenames is for product identification purposes only and does not imply endorsement.

References

  1. Bauermeister JJ, Canino G, Bird H. Epidemiology of disruptive behavior disorders. In: Greenhill L, editor. Child and Adolescent Psychiatry Clinics of North America. Philadelphia (PA): WB Saunders Company, 1994: 177–94

    Google Scholar 

  2. Murphy K, Barkley RA. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: implications for clinical diagnosis. J Atten Disord 1996; 1(3): 147–61

    Article  Google Scholar 

  3. Goldman L, Genel M, Bezman R, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 1998; 279(14): 1100–7

    Article  PubMed  CAS  Google Scholar 

  4. Weiss G, Hechtman LT. Hyperactive children grown up. New York: The Guilford Press, 1986

    Google Scholar 

  5. Mannuzza S, Klein RG, Bonagura N, et al. Hyperactive boys almost grown up: V, replication of psychiatric status. Arch Gen Psychiatry 1991; 48(1): 77–83

    Article  PubMed  CAS  Google Scholar 

  6. Fischer M. Persistence of ADHD into adulthood: it depends on whom you ask. ADHD Rep 1997; 5(4): 8–10

    Google Scholar 

  7. Biederman J, Faraone S, Mick E. Age dependent decline of ADHD symptoms revisited: impact of remission definition and symptom subtype. Am J Psychiatry 2000; 157: 816–8

    Article  PubMed  CAS  Google Scholar 

  8. Mannuzza S, Klein RG, Bessler A, et al. Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993; 50(7): 565–76

    Article  PubMed  CAS  Google Scholar 

  9. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150: 1792–8

    PubMed  CAS  Google Scholar 

  10. Biederman J, Wilens TE, Mick E, et al. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995; 152(11): 1652–8

    PubMed  CAS  Google Scholar 

  11. Shekim WO, Asarnow RF, Hess E, et al. A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state. Compr Psychiatry 1990; 31: 416–25

    Article  PubMed  CAS  Google Scholar 

  12. Levin FR, Kleber HD. Attention-deficit hyperactivity disorder and substance abuse: relationships and implications for treatment. Harv Rev Psychiatry 1995; 2(5): 246–58

    Article  PubMed  CAS  Google Scholar 

  13. Fones CS, Pollack MH, Susswein L, et al. History of childhood attention deficit hyperactivity disorder (ADHD) features among adults with panic disorder. J Affect Disord 2000; 58(2): 99–106

    Article  PubMed  CAS  Google Scholar 

  14. Alpert J, Maddocks A, Nierenberg A, et al. Attention deficit hyperactivity disorder in childhood among adults with major depression. Psychiatry Res 1996; 62: 213–9

    Article  PubMed  CAS  Google Scholar 

  15. Sachs GS, Baldassano CF, Truman CJ, et al. Comorbidity of attention deficit hyperactivity disorder with early- and late-onset bipolar disorder. Am J Psychiatry 2000; 157(3): 466–8

    Article  PubMed  CAS  Google Scholar 

  16. Shaffer D. Attention deficit hyperactivity disorder in adults. Am J Psychiatry 1994; 151: 633–8

    PubMed  CAS  Google Scholar 

  17. Hill JC, Schoener EP. Age-dependent decline of attention deficit hyperactivity disorder. Am J Psychiatry 1996; 153: 1143–6

    PubMed  CAS  Google Scholar 

  18. Spencer T, Biederman J, Wilens T, et al. Adults with attention-deficit/ hyperactivity disorder: a controversial diagnosis. J Clin Psychiatry 1998; 59 Suppl. 7: 59–68

    PubMed  Google Scholar 

  19. Achenbach TM, Howell C, McConaughy S, et al. Six-year predictors of problems in a national sample: IV. young adult signs of disturbance. J Am Acad Child Adolesc Psychiatry 1998; 37(7): 718–27

    Article  CAS  Google Scholar 

  20. Hart EL, Lahey BB, Loeber R, et al. Developmental change in attention-deficit hyperactivity disorder in boys: a four-year longitudinal study. J Abnorm Child Psychol 1995; 23(6): 729–49

    Article  PubMed  CAS  Google Scholar 

  21. Millstein RB, Wilens TE, Biederman J, et al. Presenting ADHD symptoms and subtypes in clincially referred adults with ADHD. J Atten Disord 1997; 2(3): 159–66

    Article  Google Scholar 

  22. Sergeant J. A theory of attention: an information processing perspective. In: Lyon G, Krasnegor K, editors. Attention, memory, and executive function. Baltimore (MD): Paul H Brooks, 1996: 57–71

    Google Scholar 

  23. Oosterlaan J, Logan G, Sergeant J. Response inhibition in AD/ HD, CD, comorbid AD/HD + CD, anxious, and control children: a meta-analysis of studies with the stop task. J Child Psychol Psychiatry 1998; 39: 411–25

    Article  PubMed  CAS  Google Scholar 

  24. Barkley RA. ADHD and the nature of self-control. New York: The Guilford Press, 1997

    Google Scholar 

  25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders IV. 4th ed. Washington, DC: American Psychiatric Association Press, 1994

    Google Scholar 

  26. Murphy P, Schachar R. Use of self-ratings in the assessment of symptoms of attention deficit hyperactivity disorder in adults. Am J Psychiatry 2000; 157(7): 1156–9

    Article  PubMed  CAS  Google Scholar 

  27. Ward MF, Wender PH, Reimherr FW. The Wender Utah rating scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150: 885–90

    PubMed  CAS  Google Scholar 

  28. DuPaul G, Power T, Anastopoulos A, et al. ADHD rating scale IV: checklists, norms, and clinical interpretation. New York: Guilford Press, 1998

    Google Scholar 

  29. Brown T. Brown attention deficit disorder scales. San Antonio (TX): The Psychological Corporation, 1996

    Google Scholar 

  30. Conners C, Jett J. Attention deficit hyperactivity disorder (in adults and children): the latest assessment and treatment strategies. Salt Lake City (UT): Compact Clinicals, 1999

    Google Scholar 

  31. Ratey JJ, Greenberg MS, Bemporad JR, et al. Unrecognized attention-deficit hyperactivity disorder in adults presenting for outpatient psychotherapy. J Child Adolesc Psychopharmacol 1992; 2(4): 267–75

    Article  PubMed  CAS  Google Scholar 

  32. McDermott SP, Wilens TE. Cognitive therapy for adults with ADHD. In: Brown T, editor. Subtypes of attention deficit disorders in children, adolescents, and adults. Washington, DC: American Psychiatric Press Inc, 2000: 569–606

    Google Scholar 

  33. Wilens T, McDermott S, Biederman J, et al. Cognitive therapy in the treatment of adults with ADHD: a systematic chart review of 26 cases. J Cogn Psychother 1999; 13(3): 215–26

    Google Scholar 

  34. Swanson J, McBurnett K, Christian D, et al. Stimulant medications and the treatment of children with ADHD. In: Ollendick T, Prinz R, editors. Advances in clinical child psychology. New York (NY): Plenum Press, 1995: 265–322

    Google Scholar 

  35. Greenhill L, Osman B. Ritalin: theory and practice. New York: Mary Ann Liebert, 1999

    Google Scholar 

  36. Wilens T, Spencer T. The stimulants revisited. In: Stubbe C, editor. Child and Adolescent Psychiatry Clinics of North America. 3rd ed. Philadelphia (PA): Saunders, 2000: 573–603

    Google Scholar 

  37. Wood DR, Reimherr FW, Wender PH, et al. Diagnosis and treatment of minimal brain dysfunction in adults. Arch Gen Psychiatry 1976; 33: 1453–60

    Article  PubMed  CAS  Google Scholar 

  38. Wender PH, Reimherr FW, Wood DR. Attention deficit disorder (‘minimal brain dysfunction’) in adults: a replication study of diagnosis and drug treatment. Arch Gen Psychiatry 1981; 38: 449–56

    Article  PubMed  CAS  Google Scholar 

  39. Wender PH, Reimherr FW, Wood D, et al. A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry 1985; 142: 547–52

    PubMed  CAS  Google Scholar 

  40. Gualtieri CT, Ondrusek MG, Finley C. Attention deficit disorder in adults. Clin Neuropharmacol 1985; 8: 343–56

    Article  PubMed  CAS  Google Scholar 

  41. Mattes JA, Boswell L, Oliver H. Methylphenidate effects on symptoms of attention deficit disorder in adults. Arch Gen Psychiatry 1984; 41: 1059–63

    Article  PubMed  CAS  Google Scholar 

  42. Spencer T, Wilens TE, Biederman J, et al. A double blind, crossover comparison of methylphenidate and placebo in adults with childhood onset attention deficit hyperactivity disorder. Arch Gen Psychiatry 1995; 52: 434–43

    Article  PubMed  CAS  Google Scholar 

  43. Iaboni F, Bouffard R, Minde K, et al. The efficacy of methylphenidate in treating adults with attention-deficit/hyperactivity disorder. Philadelphia (PA): American Academy of Child and Adolescent Psychiatry, 1996

    Google Scholar 

  44. Levin FR, Evans SM, McDowell D, et al. Methylphenidate treatment for cocaine abusers with adult attention-deficit/ hyperactivity disorder: a pilot study. J Clin Psychiatry 1997; 59: 300–5

    Article  Google Scholar 

  45. Wilens TE, Biederman J, Spencer TJ, et al. Controlled trial of high doses of pemoline for adults with attention-deficit/ hyperactivity disorder. J Clin Psychopharmacol 1999; 19(3): 257–64

    Article  PubMed  CAS  Google Scholar 

  46. Paterson R, Douglas C, Hallmayer J, et al. A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Aust N Z J Psychiatry 1999; 33(4): 494–502

    Article  PubMed  CAS  Google Scholar 

  47. Horrigan J, Barnhill L. Low-dose amphetamine salts and adult attention-deficit/hyperactivity disorder. J Clin Psychiatry 2000; 61: 414–7

    Article  PubMed  CAS  Google Scholar 

  48. Taylor FB. Comparing modafinil to dextroamphetamine in the treatment of adult ADHD. In: 153rd Annual Meeting of the American Psychiatric Association; 2000 May 12–18; Chicago (IL). Chicago (IL): American Psychiatric Association, 2000: NR657

    Google Scholar 

  49. Taylor FB. Comparing guanfacine and dextroamphetamine for adult ADHD: efficacy and implications. In: 153rd Annual Meeting of the American Psychiatric Association; 2000 May 12–18; Chicago (IL). Chicago (IL): American Psychiatric Association, 2000: NR658

    Google Scholar 

  50. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry 2001; 58(8): 775–82

    Article  PubMed  CAS  Google Scholar 

  51. Spencer T. A controlled, long-term trial of methylphenidate in the treatment of adults with ADHD: preliminary data. In: Annual meetings of the American Psychiatric Association; 2002 May 18–23; Philadelphia (PA). Philadelphia (PA): American Psychiatric Association, 2002

    Google Scholar 

  52. Wender PH, Wood DR, Reimherr FW. Pharmacological treatment of attention deficit disorder residual type (ADD,RT, “minimal brain dysfunction”, “hyperactivity”) in adults. Psychopharmacol Bull 1985; 21: 222–30

    PubMed  CAS  Google Scholar 

  53. Gualtieri CT, Hicks RE. Neuropharmacology of methylphenidate and a neural substrate for childhood hyperactivity. In: Greenhill L, editor. Child and Adolescent Psychiatry Clinics of North America. Philadelphia (PA): WB Saunders Company, 1985: 875–92

    Google Scholar 

  54. Conners C. Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. In: J Clin Psychiatry 1998; 59 Suppl. 7: 24–30

    Google Scholar 

  55. Faries D, Yalcin I, Harder D, et al. Validation of the ADHD rating scale as a clinican administered and scored instrument. J Atten Disord 2001; 5(2): 107–15

    Article  Google Scholar 

  56. NIMH. Clinical Global Impression (CGI). Psychopharmacol Bull 1985; 21: 839–44

    Google Scholar 

  57. Wilens T, Frazier J, Prince J, et al. A double blind comparison of pemoline in adults with ADHD: preliminary results. Scientific proceedings of the American Academy of Child and Adolescent Psychiatry. Philadelphia (PA): American Academy of Child and Adolescent Psychiatry, 1996: 121

    Google Scholar 

  58. Wender P, Reimherr F, Czajkowski L, et al. A longterm trial of methlphenidate in the treatment of adhd adults: a placebo-controlled trial and six-month follow-up. San Juan, Puerto Rico: American College of Neuropharmacology, 1995: 209

    Google Scholar 

  59. Gualtieri CT, Hicks RE, Patrick K, et al. Clinical correlates of methylphenidate blood levels. Ther Drug Monit 1984; 6(4): 379–92

    Article  PubMed  CAS  Google Scholar 

  60. Shevell M, Schreiber R. Pemoline-associated hepatic failure: a critical analysis of the literature. Pediatr Neurol 1996; 16(1): 14–6

    Article  Google Scholar 

  61. Langer DH, Sweeney KP, Bartenbach DE, et al. Evidence of lack of abuse or dependence following pemoline treatment: results of a retrospective survey. Drug Alcohol Depend 1986; 17: 213–27

    Article  PubMed  CAS  Google Scholar 

  62. Grabowski J, Roache JD, Schmitz JM, et al. Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol 1997; 17(6): 485–8

    Article  PubMed  CAS  Google Scholar 

  63. Wilens T, Faraone S, Biederman J, et al. Does the pharmacotherapy of ADHD beget later substance abuse: a metanalytic review of the literature. Pediatrics 2003; 11(1): 179–85

    Article  Google Scholar 

  64. Kratochvil CJ, Bohac D, Harrington M, et al. An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001; 11(2): 167–70

    Article  PubMed  CAS  Google Scholar 

  65. Spencer T, Biederman J, Heiligenstein J, et al. An open-label, dose-ranging study of tomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001; 11(5): 251–65

    Article  PubMed  CAS  Google Scholar 

  66. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/ hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108(5): E83

    Article  PubMed  CAS  Google Scholar 

  67. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with ADHD: a randomized, placebo-controlled study. Am J Psychiatry 2002; 159: 1896–901

    Article  PubMed  Google Scholar 

  68. Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998; 155(5): 693–5

    PubMed  CAS  Google Scholar 

  69. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003; 53: 112–20

    Article  PubMed  CAS  Google Scholar 

  70. Wender PH, Reimherr FW. Bupropion treatment of attention deficit hyperactivity disorder in adults. Am J Psychiatry 1990; 147: 1018–20

    PubMed  CAS  Google Scholar 

  71. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001; 158(2): 282–8

    Article  PubMed  CAS  Google Scholar 

  72. Wilens T, Prince J, Biederman J, et al. An open study of sustained-release bupropion in adults with ADHD and substance use disorders. Honolulu (HI): American Academy of Child and Adolescent Psychiatry, 2001

    Google Scholar 

  73. Levin FR, Evans SM, McDowell DM, et al. Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder. J Addict Dis 2002; 21(2): 1–16

    Article  PubMed  Google Scholar 

  74. Wilens T, Prince J, Spencer T, et al. An open trial of bupropion for the treatment of adults with attention deficit hyperactivity disorder and bipolar disorder. Biol Psychiatry 2003; 54: 9–16

    Article  PubMed  CAS  Google Scholar 

  75. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention deficit disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35(4): 409–32

    Article  PubMed  CAS  Google Scholar 

  76. Wilens T, Biederman J, Spencer T. Adverse effects of smoking marijuana while receiving tricyclic antidepressants. J Am Acad Child Adolesc Psychiatr 1997; 36: 45–8

    Article  CAS  Google Scholar 

  77. Wilens TE, Biederman J, Mick E. A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder. J Nerv Ment Dis 1995; 184: 48–50

    Article  Google Scholar 

  78. Wilens T, Biederman J, Prince J, et al. Six-week, double blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 1996; 153: 1147–53

    PubMed  CAS  Google Scholar 

  79. Wender PH, Wood DR, Reimherr FW, et al. An open trial of pargyline in the treatment of attention deficit disorder, residual type. Psychiatry Res 1983; 9: 329–36

    Article  PubMed  CAS  Google Scholar 

  80. Ernst M, Liebenauer L, Jons P, et al. Selegiline in adults with attention deficit hyperactivity disorder: clinical efficacy and safety. Psychopharmacol Bull 1996; 32: 327–34

    PubMed  CAS  Google Scholar 

  81. Zametkin A, Rapoport JL, Murphy DL, et al. Treatment of hyperactive children with momoamine oxidase inhibitors: clinical efficacy. Arch Gen Psychiatr 1985; 42: 962–6

    Article  PubMed  CAS  Google Scholar 

  82. Shekim WO, Masterson A, Cantwell DP, et al. Nomifensine maleate in adult attention deficit disorder. J Nerv Ment Dis 1989; 177: 296–9

    Article  PubMed  CAS  Google Scholar 

  83. Shekim WO, Antun F, Hanna GL, et al. S-adenosyl-l-methionine (SAM) in adults with ADHD, RS: preliminary results from an open trial. Psychopharmacol Bull 1990; 26: 249–53

    PubMed  CAS  Google Scholar 

  84. Adler LA, Resnick S, Kunz M, et al. Open label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacol Bull 1995; 31: 785–8

    PubMed  CAS  Google Scholar 

  85. Reimherr FW, Hedges DW, Strong RE, et al. An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder [poster no. 81]. 35th Annual Meeting of the New Clinical Drug Evaluation Unit; 1995; Orlando (FL)

  86. Findling RL, Schwartz MA, Flannery DJ, et al. Venlafaxine in adults with attention-deficit /hyperactivity disorder: an open clinical trial. J Clin Psychiatry 1996; 57(5): 184–9

    PubMed  CAS  Google Scholar 

  87. Kurlan R. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002; 58: 527–36

    Article  Google Scholar 

  88. Scahill L. Controlled clinical trial of guanfacine in ADHD youth with tic disorders. 40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30–Jun 2; Boca Raton (FL)

  89. Mattes JA. Propanolol for adults with temper outbursts and residual attention deficit disorder. J Clin Psychopharmacol 1986; 6: 299–302

    Article  PubMed  CAS  Google Scholar 

  90. Ratey J, Greenberg M, Lindem K. Combination of treatments for attention deficit disorders in adults. J Nerv Ment Dis 1991; 176: 699–701

    Article  Google Scholar 

  91. Reimherr FW, Wender PH, Wood DR, et al. An open trial of L-tyrosine in the treatment of attention deficit hyperactivity disorder, residual type. Am J Psychiatry 1987; 144: 1071–3

    PubMed  CAS  Google Scholar 

  92. Wood D, Reimherr FW. Effects of levodopa on attention deficit disorder, residual type. Psychiatry Res 1982; 6: 13–20

    Article  PubMed  CAS  Google Scholar 

  93. Wood DR, Reimherr FW, Wnder PH. The treatment of attention deficit disorder with d,l-phenylalanine. Psychiatry Res 1985; 16: 21–6

    Article  PubMed  CAS  Google Scholar 

  94. Hedges D, Reimherr FW, Rogers A, et al. An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacol Bull 1995; 31(4): 779–83

    PubMed  CAS  Google Scholar 

  95. Conners C, Levin ED, Sparrow E, et al. Nicotine and attention in adult attention deficit hyperactivity disorder. Psychopharmacol Bull 1996; 32: 67–73

    PubMed  CAS  Google Scholar 

  96. Wilens TE, Biederman J, Spencer TJ, et al. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 1999; 156(12): 1931–7

    PubMed  CAS  Google Scholar 

  97. Kuperman S, Perry PJ, Gaffney GR, et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry 2001; 13(3): 129–34

    PubMed  CAS  Google Scholar 

  98. Cephalon Inc. No benefit noted from Provigil (Modafinil) in adult attention deficit hyperactivity disorder [press release]. West Chester (PA): Cephalon Inc., 2000 Jul 31

    Google Scholar 

  99. Pomerleau O, Downey K, Stelson F, et al. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse 1995; 7: 373–8

    Article  PubMed  CAS  Google Scholar 

  100. Rezvani AH, Levin ED. Cognitive effects of nicotine. Biol Psychiatry 2001; 49(3): 258–67

    Article  PubMed  CAS  Google Scholar 

  101. Wilens T, Biederman J, Spencer T, et al. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 1999; 156: 1931–7

    PubMed  CAS  Google Scholar 

  102. Mitler MM, Hajdukovich R, Timms R, et al. Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep 1986; 9: 260–4

    PubMed  CAS  Google Scholar 

  103. Rapport MD, Carlson GA, Kelly KL, et al. Methylphenidate and desipramine in hospitalized children: I. Separate and combined effects on cognitive function. J Am Acad Child Adolesc Psychiatry 1993; 32: 333–42

    CAS  Google Scholar 

  104. Gammon GD, Brown TE. Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol 1993; 3(1): 1–10

    Article  PubMed  CAS  Google Scholar 

  105. Rapport MD, Jones JT, DuPaul GJ, et al. Attention deficit disorder and methylphenidate: group and single-subject analyses of dose effects on attention in clinic and classroom settings. J Clin Child Psychol 1987; 16: 329–38

    Article  Google Scholar 

  106. Rapport MD, Quinn SO, DuPaul GJ, et al. Attention deficit disorder with hyperactivity and methylphenidate: the effects of dose and mastery level on children's learning performance. J Abnorm Child Psychol 1989; 17(6): 669–89

    Article  PubMed  CAS  Google Scholar 

  107. Zametkin A, Liotta W. The neurobiology of attention-deficit/ hyperactivity disorder. J Clin Psychiatry 1998; 59(7): 17–23

    PubMed  Google Scholar 

  108. Dougherty D, Bonab A, Spencer T, et al. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 1999; 354: 2132–3

    Article  PubMed  CAS  Google Scholar 

  109. Krause K, Dresel SH, Krause J, et al. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 2000; 285(2): 107–10

    Article  PubMed  CAS  Google Scholar 

  110. Faraone SV, Biederman J, Weiffenbach B, et al. Dopamine D4 gene 7-repeat allele and attention deficit hyperactivity disorder. Am J Psychiatry 1999; 156(5): 768–70

    PubMed  CAS  Google Scholar 

  111. Kuczenski R. Biochemical actions of amphetamine and other stimulants. In: Creese I, editor. Stimulants: neurochemical, behavioral, and clinical perspectives. New York: Raven Press, 1983: 31–61

    Google Scholar 

  112. Elia J, Borcherding BG, Potter WZ, et al. Stimulant drug treatment of hyperactivity: biochemical correlates. Clin Pharmacol Ther 1990; 48: 57–66

    Article  PubMed  CAS  Google Scholar 

  113. Volkow N, Wang G, Fowler J, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998; 155(10): 1325–31

    PubMed  CAS  Google Scholar 

  114. Volkow ND, Wang GJ, Fowler JS, et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 2002; 43(3): 181–7

    Article  PubMed  CAS  Google Scholar 

  115. Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 1993; 32: 639–77

    Article  Google Scholar 

  116. Wilens T, Spencer T. Pharmacology of amphetamines. In: Tarter R, Ammerman R, Ott P, editors. Handbook of substance abuse: neurobehavioral pharmacology. New York: Plenum Press, 1998: 501–13

    Google Scholar 

  117. Borcherding BG, Keysor CS, Cooper TB, et al. Differential effects of methylphenidate and dextroamphetamine on the motor activity level of hyperactive children. Neuropsychopharmacology 1989; 2: 255–63

    Article  PubMed  CAS  Google Scholar 

  118. Levin E. Nicotinic systems and cognitive function. Psychopharmaology 1992; 108: 417–31

    Article  CAS  Google Scholar 

  119. Parrott AC, Winder G. Nicotine chewing gum (2mg, 4mg) and cigarette smoking: comparative effects upon vigilance and heart rate. Psychopharmacology (Berl) 1989; 97: 257–61

    Article  CAS  Google Scholar 

  120. Wesnes K, Warburton D. The effects of cigarettes of varying yield on rapid information processing performance. Psychopharmacology (Berl) 1984; 82: 338–42

    Article  CAS  Google Scholar 

  121. Jones G, Sahakian B, Levy R, et al. Effects of acute subcutaneous nicotine on attention, information and short-term memory in Alzheimer's disease. Psychopharmacology (Berl) 1992; 108: 485–94

    Article  CAS  Google Scholar 

  122. Wesnes K, Warburton DM. Smoking, nicotine, and human performance. Pharmacol Ther 1983; 21: 189–208

    Article  PubMed  CAS  Google Scholar 

  123. Pennington BF, Ozonoff S. Executive functions and developmental psychopathology. J Child Psychol Psychiatry 1996; 37(1): 51–87

    Article  PubMed  CAS  Google Scholar 

  124. Brown TE, Quinlan DM. Executive function impairments in high IQ adults with ADHD. New Haven (CT): Yale University School of Medicine, 1999

    Google Scholar 

  125. Seidman LJ, Biederman J, Faraone SV, et al. Toward defining a neuropsychology of ADHD: performance of children and adolescents from a large clinically referred sample. J Consult Clin Psychol 1997; 65(1): 150–60

    Article  PubMed  CAS  Google Scholar 

  126. Levin E, Conners C, Sparrow E, et al. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 1996; 123: 55–63

    Article  CAS  Google Scholar 

  127. Hallowell E, Ratey J. Driven to distraction. New York: Pantheon Books, 1994

    Google Scholar 

  128. Spencer T, Biederman J, Wilens T. Pharmacotherapy of attention-deficit/hyperactivity disorder: a life span perspective. In: Dickstein L, Riba M, Oldham J, editors. Review of psychiatry. Washington, DC: American Psychiatric Press, 1998: IV87–IV127

    Google Scholar 

Download references

Acknowledgements

This work was supported by federal grant USPHS DA11929 (T.W.). The author has no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. Clinical Research Program in Pediatric Psychopharmacology, W.A.C.C. 725, Boston, Massachusetts, 02114, USA

    Timothy E. Wilens

Authors
  1. Timothy E. Wilens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy E. Wilens.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wilens, T.E. Drug Therapy for Adults with Attention-Deficit Hyperactivity Disorder. Drugs 63, 2395–2411 (2003). https://doi.org/10.2165/00003495-200363220-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200363220-00002

Keywords

Search

Navigation